SER S-3 SEC Filing Analysis

Latest settled — T+5d

SER ▼ -5.73% at T+5d

SHORT call ✓ call won +5.73% · α vs SPY +6.81% · entry $1.92 → $1.81

Next anchor: T+20d in 10d

Currently $1.84 · +4.17% from $1.92 entry (call sign-flipped)

Entry anchored
May 22, 03:58 PM ET
via Databento tick

T+1d

-3.13%

call +3.13% · α +3.08%

$1.86

settled 18d ago

T+5d

-5.73%

call +5.73% · α +6.81%

$1.81

settled 12d ago

T+20d

—

call — · α —

—

in 10d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Serina Therapeutics filed an S-3 registration statement to register up to 16,450,442 shares of common stock for resale by selling stockholders, including insider Dr. Gregory H. Bailey. The shares stem from a $21.2M March/April 2026 PIPE, including PIPE shares, pre-funded/redeemable warrants, and Series A conversion shares. With 14,997,505 shares currently outstanding, potential dilution exceeds 100%. The company disclosed substantial doubt about its ability to continue as a going concern in its recent 10-Q (net loss -$6.9M in Q1 2026 vs -$4.8M in Q1 2025), making this a desperation raise registration that enables selling shareholders to exit.

Actionable Insight

Expect significant downward pressure from the massive resale registration. The 16.45M shares registered exceed the current float, and selling stockholders (including a board member) can sell at any time after the S-3 becomes effective. Watch for stockholder approval on June 17, 2026 — if denied, Dr. Bailey's 11.8M shares remain restricted. Monitor for 424B prospectus supplements indicating actual selling begins. The company's cash burn at $6.9M/quarter suggests ~3.5 quarters of runway — further dilution via the redeemable warrants ($5 strike, deeply out of the money) is unlikely, putting pressure on the stock.

Key Facts

Up to 16,450,442 shares registered for resale vs. 14,997,505 currently outstanding — more than 100% potential dilution
$21.2M March 2026 PIPE priced at $2.25/share vs. current stock price of $1.61 (premium had eroded by filing date)
Pre-Funded Warrants exercisable at $0.0001/share; Redeemable Warrants exercisable at $5.00/share
Q1 2026 net loss of -$6.9M (-$0.58 EPS) deepened from -$4.8M (-$0.49 EPS) in Q1 2025
Cash of $24.5M as of Q1 2026, plus $5.2M in April 2026; company still pre-revenue clinical-stage
Going concern warning in most recent 10-K (March 25, 2026) — substantial doubt about continued viability
NYSE American non-compliance notice received January 9, 2026; compliance plan accepted but subject to ongoing review
Board member/Co-Chair Dr. Gregory H. Bailey is largest selling stockholder, offering up to 11,830,472 shares (72% of registered shares)

Financial Impact

Potential overhang of $25.8M at May 19 closing price of $1.57/share; $21.2M gross proceeds already raised in PIPE; net loss deepened 44% YoY to -$6.9M

dilutioncash runwaynet lossmarket cap

Risk Factors

Massive overhang from 16.45M registered shares vs 15.0M outstanding — selling pressure could crush stock price
Going concern risk — company has no revenue, deepening losses, and a going concern warning
NYSE American delisting risk — company received non-compliance notice in January 2026
Insider selling by Co-Chair Dr. Bailey (11.8M shares) signals potential lack of confidence
Series A preferred holders forced to convert at $2.25 vs original $5.18, creating selling pressure from holders looking to exit

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

83% bullish (6 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
S-3 Filing (Primary)	0001493152-26-025007
Exhibit: ex107.htm	0001493152-26-025007
Exhibit: ex5-1.htm	0001493152-26-025007
Exhibit: ex23-1.htm	0001493152-26-025007
Document: 0001493152-26-025007-index-headers.html	0001493152-26-025007
Document: 0001493152-26-025007-index.html	0001493152-26-025007
Document: 0001493152-26-025007.txt	0001493152-26-025007

6 reports for SER

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SER — sortable, filterable
	Type				Now
Jun 4, 2026 9d ago	EFFECT BEARISH ★ 7/10	$1.86 $1.88	▼ −1.08%	▼ −3.67%	$1.84 (+1.08%)
May 26, 2026 17d ago	Insider Cluster MIXED ★ 5/10	$1.80 $1.95	▲ +8.33%	▲ +7.78%	$1.84 (+2.22%)
May 26, 2026 17d ago	Insider Cluster BEARISH ★ 5/10	$1.80 $1.95	▼ −8.33%	▼ −7.78%	$1.84 (−2.22%)
May 22, 2026 21d ago	S-3 BEARISH ★ 7/10	$1.92 $1.86	▲ +3.13%	▲ +3.08%	$1.84 (+4.17%)
Mar 27, 2026 11w ago	10-K/A NEUTRAL ★ 2/10	$2.27 $1.80	▼ −20.70%	▼ −20.35%	$1.84 (−18.94%)
Mar 25, 2026 11w ago	Press Release MIXED ★ 7/10	$2.61 $2.27	▼ −13.03%	▼ −11.35%	$1.84 (−29.50%)

US Market Status

Market Closed — Opens Mon (45h 28m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access